Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Kennedy Capital Management LLC

Kennedy Capital Management LLC lifted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,459 shares of the medical research company's stock after acquiring an additional 13,600 shares during the period. Kennedy Capital Management LLC owned approximately 0.08% of Exact Sciences worth $8,286,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of EXAS. Asset Planning Inc bought a new stake in shares of Exact Sciences in the 4th quarter valued at about $40,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $43,000. AlphaQuest LLC raised its stake in Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after acquiring an additional 913 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Exact Sciences during the fourth quarter worth $66,000. Finally, Quantinno Capital Management LP bought a new stake in shares of Exact Sciences during the third quarter worth about $223,000. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Stock Down 1.7 %

EXAS stock traded down $0.75 during midday trading on Wednesday, hitting $42.92. The company's stock had a trading volume of 1,276,366 shares, compared to its average volume of 2,594,716. Exact Sciences Co. has a 52-week low of $39.97 and a 52-week high of $72.83. The firm has a 50-day simple moving average of $46.50 and a 200-day simple moving average of $55.48. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm has a market capitalization of $7.97 billion, a P/E ratio of -7.71 and a beta of 1.14.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, equities analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent analyst reports. Benchmark reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. Royal Bank of Canada initiated coverage on Exact Sciences in a research report on Thursday, March 13th. They set a "sector perform" rating and a $52.00 target price on the stock. Barclays decreased their price objective on shares of Exact Sciences from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. William Blair restated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Finally, Bank of America reduced their target price on Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Exact Sciences has an average rating of "Moderate Buy" and an average price target of $69.25.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.